Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines. [Eine einarmige, offene, multizentrische Phase-II-Studie zum Nachweis der Wirksamkeit und Sicherheit von BIBW 2992 (Afatinib) in Kombination mit Vinorelbin zur Behandlung von Patientinnen mit metastasierendem Brustkrebs mit intermediärer HER2-Expression (HER2 2+ in der Immunhistochemie, Fluoreszenz in situ Hybridisierung (FISH) negativ) nach Versagen der Erstbehandlung der metastasierenden Erkrankung und Vorbehandlung mit Anthrazyklinen].

Trial Profile

Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines. [Eine einarmige, offene, multizentrische Phase-II-Studie zum Nachweis der Wirksamkeit und Sicherheit von BIBW 2992 (Afatinib) in Kombination mit Vinorelbin zur Behandlung von Patientinnen mit metastasierendem Brustkrebs mit intermediärer HER2-Expression (HER2 2+ in der Immunhistochemie, Fluoreszenz in situ Hybridisierung (FISH) negativ) nach Versagen der Erstbehandlung der metastasierenden Erkrankung und Vorbehandlung mit Anthrazyklinen].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Afatinib (Primary) ; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 May 2012 New source identified and integrated (EudraCT2011-001765-41; European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top